ABVX vs ARDX vs PTGX vs ABBV vs JNJ

For growth investors, Ardelyx, Inc.

(ARDX) is the stronger pick with 22. 1% revenue growth year-over-year, versus -89. 4% for Protagonist Therapeutics, Inc. (PTGX). Johnson & Johnson (JNJ) offers the better valuation at 41. 6x trailing P/E (20. 8x forward), making it the more compelling value choice. Analysts rate Abivax S. A. (ABVX) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Johnson & Johnson (JNJ) is the cheapest at 41.

6x versus AbbVie Inc. at 96. 1x. On forward P/E, AbbVie Inc. is actually cheaper at 16. 0x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Abivax S.

A. (ABVX) delivered a total return of +1063%, compared to +60. 1% for Johnson & Johnson (JNJ). Over 10 years, the gap is even starker: ABVX returned +1063% versus JNJ's +142. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Johnson & Johnson (JNJ) is the lower-risk stock at 0.

01β versus Abivax S. A. 's 1. 05β — meaning ABVX is approximately 13859% more volatile than JNJ relative to the S&P 500. On balance sheet safety, Protagonist Therapeutics, Inc. (PTGX) carries a lower debt/equity ratio of 2% versus 127% for Ardelyx, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ardelyx, Inc.

(ARDX) is pulling ahead at 22. 1% versus -89. 4% for Protagonist Therapeutics, Inc. (PTGX). On earnings-per-share growth, the picture is similar: AbbVie Inc. grew EPS -0. 8% year-over-year, compared to -148. 5% for Protagonist Therapeutics, Inc.. Over a 3-year CAGR, ARDX leads at 98. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Johnson & Johnson (JNJ) is the more profitable company, earning 15.

8% net margin versus -282. 8% for Protagonist Therapeutics, Inc. — meaning it keeps 15. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABBV leads at 32. 8% versus -343. 6% for PTGX. At the gross margin level — before operating expenses — PTGX leads at 97. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, AbbVie Inc.

(ABBV) trades at 16. 0x forward P/E versus 27. 2x for Protagonist Therapeutics, Inc. — 11. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ARDX: 198. 8% to $17. 00.

In this comparison, ABBV (2.

9% yield), JNJ (2. 0% yield) pay a dividend. ABVX, ARDX, PTGX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 14), 2. 9% yield, +362. 2% 10Y return). Both have compounded well over 10 years (ABBV: +362. 2%, ARDX: +162. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ABVX is a small-cap quality compounder stock; ARDX is a small-cap high-growth stock; PTGX is a small-cap quality compounder stock; ABBV is a large-cap quality compounder stock; JNJ is a large-cap quality compounder stock. ABBV, JNJ pay a dividend while ABVX, ARDX, PTGX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.